Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 2
2(50.0%)
4Total
N/A(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00718627Phase 2Completed

Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders

Role: lead

NCT01195753Phase 2Terminated

Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders

Role: lead

NCT01549015Not ApplicableCompleted

Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function

Role: lead

NCT01002469Not ApplicableCompleted

Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment

Role: lead

All 4 trials loaded